OR WAIT null SECS
Solentim and ATUM have announced a technology collaboration agreement that will focus on the creation of an efficient cell line development solution for biotherapeutic drug developers.
Solentim, specialist in cell-line development instrumentation, and ATUM, a bioengineering company, have announced a technology collaboration agreement that will focus on the creation of an efficient cell line development solution for biotherapeutic drug developers.
Creation of the cell-line development solution will be achieved through the integration of Solentim’s verified in-situ plate seeding (VIPS) hardware along with ATUM’s expression technology, Leap-In Transposase, it was revealed in a Jan. 14, 2019 press release.
“This collaboration allows Solentim and ATUM to offer a unique integrated solution to our customers and significantly accelerate stable cell line development workflows,” said Ian Taylor, commercial director of Solentim. “This approach means that scientists no longer need to pre-screen for high producing clones (e.g., using fluorescence detection to measure secretion from single cells or colonies). Instead, using the Leap-In Transposase technology, almost every transfected cell is a high producing clone. Combining this with high seeding efficiencies from VIPS has huge practical benefits to the workflow …”
“Establishing and isolating the most suitable cell lines producing [protein pharmaceuticals] is a major manufacturing bottleneck,” added Jeremy Minshull, CEO of ATUM. “We are extremely excited to combine our advanced bioengineering tools with the instrumentation technology of Solentim to accelerate the discovery and development process.”